FILTER
FILTERED INTERVIEW RESULTS
Swapnil Shah
MANAGING DIRECTOR, ESPEE GROUP
Espee Group speaks about how the demand for drugs is changing.
Shankar Musunuri
CHAIRMAN, CEO & CO-FOUNDER, OCUGEN
Ocugen explains its work on cures for unmet needs in the ophthalmology space and COVID-19 vaccine development.
Brian Frenzel
PRESIDENT & CEO, TOSK
Tosk explains how it is successfully developing drugs to counter the side effects of cancer therapies.
Prasad Raje
CEO, LGM PHARMA
LGM Pharma explains how working with a smaller CDMO with extensive experience and partnerships can be beneficial.
Ramin Cyrus
VICE PRESIDENT MARKETING, LONZA CAPSULES AND HEALTH INGREDIENTS
Lonza Capsules and Health Ingredients comments on market trends.
Vivek Sharma
CEO, ADARE PHARMA SOLUTIONS
Adare Pharma Solutions explains how it is expanding its range as a leading technology-driven CDMO.
John Huang
CEO, THEWELL BIOSCIENCE
TheWell Bioscience is a biomedical technology company providing innovative 3D cell platforms for drug discovery, cell therapy and personalized medicine.
Robert Bloder
CHIEF BUSINESS OFFICER, ASCENDIA PHARMACEUTICALS
Ascendia Pharmaceuticals recounts the requirements to succeed in the CDMO space.
Jigar Raythatha
PRESIDENT & CEO, CONSTELLATION PHARMACEUTICALS
Constellation Pharmaceuticals explains its therapy for myelofibrosis and introduces its discovery engine.
Brad Payne & Chris Blanton & Morgan Brandt
COO & VP AND GENERAL MANAGER & GLOBAL DIRECTOR, DIGITAL PRODUCTS, PCI PHARMA SERVICES
PCI Pharma Services relates its rapid expansion in both services and geography.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2025 - Digital Interactive
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
